Time course and prognostic significance of hemostatic changes in sepsis: Relation to tumor necrosis factor-α

Critical Care Medicine

Volumn 27, Issue 7, 1999, Pages 1303-1308

  Martínez, María A ^a,b   Peña, José M ^a   Fernández, Aurora ^a   Jiménez, Manuel ^a   Juárez, Salvador ^a   Madero, Rosario ^a   Vázquez, Juan J ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b NONE   (Spain)

Author keywords

Coagulation; Fibrinolysis; Hemostasis; Sepsis; Tumor necrosis factor

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; FIBRINOPEPTIDE A; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SEPSIS; THROMBOCYTE COUNT;

ADULT; APACHE; BIOLOGICAL MARKERS; BLOOD COAGULATION; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; PROSPECTIVE STUDIES; SEPSIS; SPAIN; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442753339     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199907000-00017     Document Type: Article

References (27)

1. Harris LH, Musher DM, Bloom K, et al: Manifestations of sepsis. Arch Intern Med 1987; 147:1895-1906
2. Bone RC: The pathogenesis of sepsis. Ann Intern Med 1991; 115:457-469
3. Bone RC: Sepsis and coagulation: An important link. Chest 1992; 101:594-595
4. Levi M, Ten Cate H, Van der Poll T, et al: Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270:875-879
5. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474
6. Massignon D, Lepape A, Bienvenu J, et al: Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state. Haemostasis 1994; 24:36-48
7. Hesselvik JF, Blomback M, Brodin B, et al: Coagulation, fibrinolysis, and Kallikrein systems in sepsis: Relation to outcome. Crit Care Med 1989; 17:724-733
8. Lorente JA, García-Frade LJ, Landín L, et al: Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103:1536-1542
9. American College of Chest Physicians-Society of Critical Care Medicine Consensus Group: Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-875
10. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829
11. Caen J, Larrieu MJ, Sanama M: L'hémostase: Méthodes d'exploration et Diagnostic Pratique. Paris, Expansion Scientifique, 1975
12. Von Claus A: Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957; 17:237-246
13. Corrigan JJ, Ray WL, May N: Changes in the blood coagulation system associated with septicemia. N Engl J Med 1968; 279:851
14. van der Poll T, Buller HR, Ten Cate H, et al: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622-1627
15. Philippé J, Offner F, Declerck PJ, et al: Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemostasis 1991; 65:291-295
16. Voss R, Mathias FR, Borkowski G, et al: Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 1990; 75:99-105
17. Páramo JA, Pérez JL, Serrano M, et al: Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor in patients with sepsis. Thromb Haemostasis 1990; 64:3-6
18. Suffredini AF, Harpel PC, Parrillo JE: Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320:1165-1172
19. Pralong G, Calandra T, Glauser M-P, et al: Plasminogen activator inhibitor 1: A new prognostic marker in septic shock. Thromb Haemostasis 1989; 61:459-462
20. Kruitoff EKO, Gudinchet A, Bachman F: Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemostasis 1988; 59: 7-12
21. D'Angelo A, Kluflt C, Verheijen JH, et al: Fibrinolytic shutdown after surgery: Impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest 1985; 15:308-312
22. Risberg B, Medegard A, Heideman M, et al: Early activation of humoral proteolytic systems in patients with multiple trauma. Crit Care Med 1986; 14:917-921
23. Páramo JA, Colucci M, Collen D, et al: Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ 1985; 291:574-577
24. Damas P, Reuter A, Gysen P, et al: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17:975-978
25. Martin C, Saux P, Mege JL, et al: Prognostic values of serum cytokines in septic shock. Intensive Care Med 1994; 20:272-277
26. Conway EM, Bach R, Rosenberg RD, et al: Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53:231-241
27. Moore KL, Esmon CT, Esmon NL: Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73:159-165